RARITAN, New Jersey, Feb. 3 -- Johnson and Johnson Innovative Medicine issued the following news release on Feb. 2, 2026:

* * *

Real-world head-to-head analysis shows 51% reduction in risk of death for patients with metastatic castration-sensitive prostate cancer treated with ERLEADA(R) (apalutamide) versus darolutamide without docetaxel through 24 months

First ever head-to-head analysis compares overall survival outcomes of ERLEADA(R) versus darolutamide

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Submit Form Click here for more information about our products